What Causes Low Glucose? Symptoms and Treatment

Low glucose, or hypoglycaemia, occurs when blood glucose falls to a level that impairs normal cellular function, most commonly below 4 mmol/L in people with diabetes. It can result from insulin or sulphonylurea medication, missed meals, alcohol, prolonged fasting, or underlying medical conditions such as insulinoma or adrenal insufficiency. Recognising the causes, warning signs, and correct treatment is essential, as severe episodes can lead to seizures or loss of consciousness. This article explains who is most at risk, how hypoglycaemia is diagnosed and managed on the NHS, and what dietary and lifestyle steps can help prevent episodes.

What causes low glucose levels in the body?

Low glucose is most commonly caused by excess insulin or sulphonylurea medication in people with diabetes, but also by alcohol, prolonged fasting, reactive hypoglycaemia, or conditions such as insulinoma and Addison's disease.

Low glucose levels, clinically known as hypoglycaemia, occur when blood glucose falls to a level that impairs normal cellular function. In people with diabetes, a blood glucose reading of usually below 4 mmol/L is the accepted treatment threshold; in people without diabetes, there is no single fixed numerical cut-off, and diagnosis relies on Whipple's triad (compatible symptoms, a documented low plasma glucose during the episode, and resolution of symptoms after glucose correction).^[1][2] Glucose is the body's primary fuel source, and its concentration in the blood is tightly regulated by hormones, principally insulin and glucagon. When this balance is disrupted, blood glucose can drop to levels that impair normal cellular function, particularly in the brain.

The most frequent cause in people with diabetes is taking too much insulin or a sulphonylurea medication (such as gliclazide or glibenclamide) relative to carbohydrate intake or physical activity.^[23][2] These medicines lower blood glucose as part of their intended action, but an excess dose, a missed meal, or unexpected exercise can push levels too low. Other medicines that can precipitate hypoglycaemia include quinine, pentamidine, and high-dose salicylates; factitious hypoglycaemia from covert insulin or sulphonylurea use is also recognised, though uncommon.^[4][5]

Beyond diabetes treatment, other recognised causes include:

• Reactive hypoglycaemia: a drop in blood glucose occurring one to three hours after a carbohydrate-rich meal, thought to involve an exaggerated insulin response, though the mechanism is not fully established.^[3] Post-bariatric surgery hypoglycaemia is a distinct and increasingly recognised variant.

• Alcohol consumption: alcohol suppresses the liver's ability to release stored glucose (glycogen), particularly when drinking without eating

• Prolonged fasting or severe calorie restriction: depletes glycogen stores, leaving the body unable to maintain adequate blood glucose

• Certain medical conditions: including insulinoma (a rare insulin-secreting tumour), Addison's disease, severe liver disease, and some kidney disorders

• Sepsis or critical illness: can disrupt glucose regulation through multiple mechanisms

In people without diabetes, true hypoglycaemia is uncommon and usually signals an underlying medical condition that warrants investigation. Understanding the root cause is essential before any treatment plan is considered.

Who is most at risk of low blood sugar in the UK?

People with type 1 or type 2 diabetes using insulin or sulphonylureas are at highest risk, with older adults, those with impaired hypoglycaemia awareness, and people with chronic kidney disease particularly vulnerable.

People living with type 1 or type 2 diabetes who use insulin or sulphonylurea medicines are at the highest risk of hypoglycaemia in the UK. According to NHS and NICE guidance, hypoglycaemia is one of the most common acute complications of diabetes management, and its frequency increases with tighter glycaemic control targets.

Within the diabetes population, certain subgroups face a particularly elevated risk:

• People with type 1 diabetes: who depend entirely on exogenous insulin and must carefully balance dose, diet, and activity

• Older adults: who may have impaired awareness of hypoglycaemia symptoms, irregular eating patterns, polypharmacy, and reduced kidney function that slows drug clearance

• People with impaired hypoglycaemia awareness: a condition in which the body's counter-regulatory response is blunted, meaning warning symptoms appear later or not at all

• Those with chronic kidney disease: reduced renal clearance prolongs the action of insulin and some oral agents

• Pregnant women with diabetes: whose insulin requirements fluctuate significantly across trimesters

• People taking beta-blockers or those with autonomic neuropathy: these conditions can blunt or mask the adrenergic warning symptoms of hypoglycaemia, increasing the risk of progression to severe episodes without early alert^[20][21]

Beyond diabetes, individuals with a history of bariatric surgery, those following very low-calorie diets, and people with certain endocrine disorders (such as adrenal insufficiency or hypopituitarism) are also at elevated risk. Heavy or binge drinkers, particularly those who drink without eating, represent another at-risk group.

For people managing their weight with GLP-1 receptor agonist medicines such as semaglutide (Wegovy, which is licensed in the UK for chronic weight management) or tirzepatide (Mounjaro, which is licensed in the UK for both type 2 diabetes and chronic weight management), the risk of hypoglycaemia is generally low when these medicines are used alone.^[10][11] Ozempic, which also contains semaglutide, is licensed in the UK for type 2 diabetes rather than weight management.^[16][17] The risk of hypoglycaemia with any of these medicines increases if they are combined with insulin or a sulphonylurea. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where clinical suitability is assessed before any treatment is considered.

What are the warning signs and symptoms to watch for?

Early symptoms include shakiness, sweating, palpitations, and hunger; later neuroglycopenic symptoms include confusion, slurred speech, and in severe cases seizures or loss of consciousness.

The warning signs of hypoglycaemia typically begin when blood glucose falls to usually below 4 mmol/L in people with diabetes and include shakiness, sweating, palpitations, pallor, and a feeling of intense hunger. These early symptoms are driven by the body's adrenaline response, which is triggered as glucose levels decline and the brain signals an emergency.

Symptoms are broadly grouped into two categories:

Adrenergic (early) symptoms:

• Trembling or shakiness

• Sweating

• Rapid or pounding heartbeat (palpitations)

• Anxiety or irritability

• Pallor

• Hunger

Neuroglycopenic (later) symptoms, which arise when the brain itself is deprived of glucose:

• Difficulty concentrating or confusion

• Slurred speech

• Blurred or double vision

• Drowsiness or unusual fatigue

• Headache

• In severe cases, seizures or loss of consciousness

It is important to note that some people, particularly those with long-standing diabetes or frequent hypoglycaemic episodes, develop impaired hypoglycaemia awareness. In this condition, the adrenergic warning symptoms are diminished or absent, meaning the person may progress directly to neuroglycopenic symptoms without the usual early alert. Beta-blockers and autonomic neuropathy can similarly blunt adrenergic symptoms. This significantly increases the risk of severe hypoglycaemia.

Clinically, severe hypoglycaemia is defined as an episode requiring assistance from another person to treat, regardless of whether the person is conscious.^[3] Loss of consciousness represents the most serious end of this spectrum.

Anyone who loses consciousness or cannot be roused should be treated as a medical emergency: call 999 immediately. For urgent advice when symptoms are present but the person is conscious and able to swallow, contact NHS 111. Mild to moderate episodes that resolve with treatment should still be discussed with a GP, particularly if they are recurring, to review the underlying cause and adjust any relevant medication.

Driving safety: People with diabetes who drive must follow DVLA guidance on hypoglycaemia. This includes checking blood glucose before driving and at regular intervals on longer journeys, and not driving if blood glucose is below 5 mmol/L. If a hypo occurs while driving, the driver should stop safely, remove the keys from the ignition, move to the passenger seat, treat the hypo, and wait at least 45 minutes after blood glucose has returned to normal before driving again. The DVLA publishes specific guidance for drivers with diabetes, and any concerns should be discussed with a GP or diabetes team.

How is low glucose diagnosed and treated by the NHS?

Diagnosis uses blood glucose measurement or Whipple's triad; mild episodes are treated with 15 to 20 g of fast-acting carbohydrate, while severe episodes require glucagon or intravenous dextrose and a 999 call.

Hypoglycaemia is diagnosed by measuring blood glucose. In people with diabetes, a reading of usually below 4 mmol/L in a symptomatic individual is the accepted treatment threshold. In people without diabetes, diagnosis relies on Whipple's triad: compatible symptoms occurring alongside a documented low plasma glucose during the episode, with resolution of symptoms after glucose correction. A finger-prick capillary blood glucose test is the most immediate tool in practice. Continuous glucose monitors (CGMs) are increasingly used in people with diabetes to detect and track episodes in real time; however, during a symptomatic episode, it is advisable to confirm a CGM low reading with a finger-prick capillary test, as interstitial lag or sensor compression can occasionally cause discrepancies.

For people with diabetes, NICE and JBDS guidance recommends that hypoglycaemia be treated promptly:

• Mild to moderate hypoglycaemia (conscious and able to swallow): take 15 to 20 g of fast-acting carbohydrate, such as 150 to 200 ml of a sugary drink (not diet), glucose tablets, or glucose gel. Recheck blood glucose after 15 minutes and repeat if still below 4 mmol/L. Once recovered, follow with a longer-acting carbohydrate snack if the next meal is more than an hour away.

• Severe hypoglycaemia (requiring assistance from another person, or unconscious): do not give anything by mouth. Call 999. Glucagon can be administered by a trained carer or family member using a glucagon injection kit or nasal glucagon (Baqsimi), both of which are available on NHS prescription for people at risk. It is important to note that glucagon works by stimulating the liver to release stored glycogen; its effectiveness is therefore reduced or absent when glycogen stores are depleted, as may occur after prolonged fasting or heavy alcohol consumption.^[3][18] In these situations, or if glucagon is ineffective, hospital treatment with intravenous dextrose is required.

Sulphonylurea-induced hypoglycaemia carries a particular risk of recurrence due to the prolonged action of these medicines. Episodes caused by a sulphonylurea may warrant hospital assessment and observation even after initial recovery.

For people without diabetes who experience recurrent hypoglycaemia, the NHS approach involves investigating the underlying cause. This may include fasting blood glucose tests, insulin and C-peptide levels, and specialist referral to endocrinology. Treatment is directed at the root cause rather than glucose supplementation alone. Medication review by a GP is essential if a prescribed drug is suspected to be contributing.

If you experience suspected side effects from any medicine, you can report these to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Can diet and lifestyle changes help prevent hypoglycaemia?

Regular meals, lower-GI carbohydrates, balancing carbohydrate with protein and fat, and avoiding alcohol on an empty stomach can reduce hypoglycaemic episodes alongside medical management.

Dietary and lifestyle adjustments can meaningfully reduce the frequency and severity of hypoglycaemic episodes, particularly in people with diabetes or reactive hypoglycaemia, though they work alongside rather than replacing medical management. The goal is to maintain a steadier blood glucose profile throughout the day by moderating the speed and quantity of glucose entering the bloodstream.

Key dietary strategies supported by NHS and NICE guidance include:

• Eating regular meals and snacks: avoiding long gaps between eating helps prevent glucose from falling too low, particularly for people on insulin or sulphonylureas. For reactive hypoglycaemia, smaller and more frequent low-GI meals and limiting high free-sugar foods are particularly relevant.

• Choosing lower glycaemic index (GI) carbohydrates: foods such as oats, lentils, wholegrain bread, and most vegetables release glucose more gradually than refined carbohydrates, reducing the risk of sharp rises followed by reactive dips

• Balancing carbohydrate with protein and healthy fats: this slows gastric emptying and blunts post-meal glucose fluctuations

• Avoiding alcohol on an empty stomach: if alcohol is consumed, it should be accompanied by food to reduce the risk of alcohol-induced hypoglycaemia

• Adjusting carbohydrate intake around exercise: physical activity increases glucose uptake by muscles; people on insulin may need to reduce their dose or increase carbohydrate intake before, during, or after exercise, under guidance from their diabetes team

Lifestyle factors such as consistent sleep patterns, stress management, and regular physical activity also contribute to more stable glucose regulation over time. People with diabetes are encouraged to work with a diabetes specialist nurse or dietitian to personalise these strategies.

For those using weight-management medicines alongside insulin or a sulphonylurea, significant changes to calorie intake should prompt a prescriber-led review and possible dose adjustment of the glucose-lowering medicine, as reduced food intake can increase the risk of hypoglycaemia. Regular self-monitoring of blood glucose, where recommended, remains one of the most effective tools for identifying patterns and preventing future episodes.

Scientific References

1. Low blood glucose (hypoglycaemia) in type 1 diabetes – NICE NG18 information for the public.
2. Low blood sugar (hypoglycaemia).
3. Hypoglycaemia | Treatment summaries – BNF – NICE.
4. Seltzer HS. Drug-induced hypoglycemia. A review of 1418 cases. 1989..
5. Drug-induced disorders of glucose metabolism. Mechanisms and management. Drug Safety. 1996..
6. Madison LL. Ethanol-induced hypoglycemia. II. Mechanism of suppression of hepatic gluconeogenesis. Diabetes. 1967..
7. Arky RA et al. Irreversible Hypoglycemia: A Complication of Alcohol and Insulin. JAMA. 1968..
8. Hypoglycemia in non-diabetic in-patients at a teaching referral hospital in Iran. Journal of Diabetes and Metabolic Disorders. 2024..
9. Not Just an Accident: A Case of Insulinoma. Cureus. 2023..
10. First GLP-1 tablet for weight loss approved in the UK. 2026..
11. Wegovy | European Medicines Agency (EMA).
12. Semaglutide | Drugs – BNF – NICE.
13. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
14. Mounjaro | European Medicines Agency (EMA).
15. Tirzepatide | Drugs – BNF – NICE.
16. GLP-1 medicines for weight loss and diabetes: what you need to know.
17. Semaglutide: a medicine to manage type 2 diabetes or obesity – NHS.
18. Baqsimi | European Medicines Agency (EMA).
19. Diabetes mellitus: assessing fitness to drive – GOV.UK.
20. Koracevic G et al. Beta Blockers can Mask not only Hypoglycemia but also Hypotension. 2022..
21. Beta-adrenoceptor blocking drugs | Treatment summaries – BNF – NICE.
22. Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in normal subjects. Metabolism. 1981..
23. Hypoglycemia induced by oral hypoglycemic agents. Records of the French Regional Pharmacovigilance Centers 1985–1990. Annales de medecine interne. 1992..

Frequently Asked Questions